Extracellular @entity5 markers may have potential role in the follow-up of @entity1 with @entity320 , in therapy monitoring and in prediction of prognosis. In our article circulating @entity5 markers in @entity320 ( @entity320 inhibitory activity, lipid bound @entity3167 , neuron specific enolase, TA90 immune complex, @entity4483 protein, @entity49364 , @entity11442 , cytokines, metalloproteinases, LDH) were reviewed. Among @entity320 markers the @entity4483 protein is the most investigated. @entity4483 protein has high specificity, appropriate sensitivity and proved to be significant prognostic factor independent from stages. High serum values are associated with shorter survival. However, before @entity4483 monitoring immunohistochemistry for the detection of @entity4483 is required. In the case of @entity320 with low expression serum @entity4483 monitoring may not be sensitive enough to follow disease progression. Although the serum concentration of @entity49364 did not prove to be independent prognostic factor in our previous studies comprising the highest @entity1 number in the literature, the marker was suggested for therapy monitoring. The survival analysis indicated that the elevated @entity49364 level predicts shorter survival. In spite of the calculated low correlation between the two markers, parallel elevation of @entity4483 protein and @entity49364 indicated shorter survival. On the basis of the literature LDH is the most appropriate @entity5 marker in stage IV to predict prognosis, but its sensitivity and specificity could not achieve that of @entity4483 protein. @entity4483 and LDH proved to be similarly reliable in respect to the clinical outcome. Determination of serum concentration of MIA and @entity11442 are also reliable markers in @entity320 . The other investigated markers are not well known yet or do not provide useful information to the clinicians.

[Laboratory markers of XXXX progression].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity3167 :: ('MESH:D019158', 'Chemical') :: ['sialic acid'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity4483 :: ('6285', 'Gene') :: ['S-100B'] @entity49364 :: ('MESH:D003548', 'Chemical') :: ['5-S-cysteinyldopa'] @entity11442 :: ('7299', 'Gene') :: ['tyrosinase'] @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'malignant melanomas', 'laboratory melanoma', 'malignant melanoma']
@entity320 :: (MESH:D008545,Disease) :: ['melanoma']
